



4 - 3 - 06

IFW/ 1746 ✓

EXPRESS MAIL NO.: EV452777065US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jerome B. Zeldis

Confirmation No.: 9742

Application No: 10/534,324

Group Art Unit: To Be Assigned

Filed: May 5, 2005

Examiner: To Be Assigned.

For: METHODS OF USING AND
COMPOSITIONS COMPRISING SELECTIVE
CYTOKINE INHIBITORY DRUGS FOR THE
TREATMENT AND MANAGEMENT OF
MYELOPROLIFERATIVE DISEASES

Jones Day Docket No.: 9516-086-999
(CAM No.: 501872-999085)

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Applicant hereby directs the Examiner's attention to References **A67-A68**, and **C46-C52**, listed on the attached Substitute For form 1449/PTO entitled "Information Disclosure Statement by Applicant." This Information Disclosure Statement supplements the Information Disclosure Statement filed on March 3, 2006.

Copies of references C46-C52 are submitted herewith. Copies of References A67-A68, being U.S. publication documents are not submitted herewith pursuant to 37 C.F.R. § 1.98(a)(2)(ii).

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./

NYJD. 1616943.1

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits. Therefore, no fee is believed to be due. Should any fee be required, however, please charge such fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: March 31, 2006

 (Reg. No.)
Yeahsil Moon 52,042
For: Anthony M. Insogna 35,203
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 790-9090

Enclosures



Substitute for Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
9516-086-999
(CAM No. 501872-999085)

APPLICATION NO.
10/534,324

APPLICANT:

Zeldis

FILING DATE:

May 5, 2005

ART UNIT: CONF. NO.:

9742

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*	DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A67	2003-0176332	09/18/2003	Olmarker et al.
	A68	2004-0067953	04/08/2004	Stein et al.

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
					YES NO
	B01				
	B02				

NON PATENT LITERATURE DOCUMENTS (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published, etc.)

EXAMINER'S INITIALS*	
C46	DREDGE et al., 2002, "Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects," <i>Br. J. Cancer</i> 87(10):1166-1172
C47	DREDGE et al., 2005, "Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro," <i>Microvasc. Res.</i> 69(1-2):56-63
C48	MAN et al., 2003, "Alpha-fluoro-substituted thalidomide analogues," <i>Bioorg. Med. Chem. Lett.</i> 13(20):3415-3417
C49	MOLOSTVOV et al., 2004, "The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures," <i>Br. J. Haematol.</i> 124(3):366-375
C50	PAYVANDI et al., 2004, "Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner," <i>Cell Immunol.</i> 230(2):81-88
C51	SCHAFFER et al., 2003, "Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs," <i>J. Pharmacol. and Exp. Ther.</i> 305(3):1222-1232
C52	ZELDIS et al., 2003, "Potential new therapeutics for Waldenstrom's macroglobulinemia," <i>Semin. Oncol.</i> 30(2):275-281

EXAMINER

/Marcos Sznaidman/

DATE CONSIDERED

10/27/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPPE 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.